Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy.
Department of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, University Hospital "P. Giaccone", Palermo, Italy.
Ann Clin Transl Neurol. 2023 Jun;10(6):1025-1034. doi: 10.1002/acn3.51785. Epub 2023 May 4.
Vaccines are a major achievement of science, and new vaccines against SARS-CoV-2 are protecting the entire population from a life-threatening infection. Although several neurological complications or worsening of pre-existing neurological conditions after vaccination have been observed, whether a biological plausibility exist between new vaccines against-SARS-CoV-2 and neurological consequences is unclear. The aim of this study is to evaluate whether vaccines against SARS-CoV-2 induce systemic or cerebrospinal fluid alterations in patients with neurological disorders.
Patients who underwent lumbar puncture (LP) between February 2021 and October 2022 were enrolled. Serum C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), cerebrospinal fluid total protein content (CSF-TPc), glucose CSF/serum ratio, number of CSF cells per cubic millimeter, and CSF neurofilament light chain (CSF-NfL) were compared between unvaccinated and vaccinated patients.
A total of 110 patients were included and fitted into three groups according firstly to vaccination status (vaccinated and unvaccinated) and then to time from last dose of vaccine to LP (within or after 3 months). TPc, CSF/S ratio, number of cells per cubic millimeter, CSF-NfL, CRP, and NLR were not different between groups (all p > 0.05), and also, they did not differ neither according to age nor diagnosis. No relevant differences between groups were also noticed when the at-risk time window was set to 6 weeks.
No signs of neuroinflammation, axonal loss and systemic inflammation were found in patients with neurological disorders after anti-SARS-CoV-2 vaccination compared with unvaccinated ones.
疫苗是科学的重大成就,针对 SARS-CoV-2 的新型疫苗正在保护全人群免受危及生命的感染。尽管接种疫苗后已经观察到几种神经系统并发症或原有神经系统疾病恶化,但针对 SARS-CoV-2 的新型疫苗与神经系统后果之间是否存在生物学相关性尚不清楚。本研究旨在评估针对 SARS-CoV-2 的疫苗是否会引起神经系统疾病患者出现全身或脑脊液改变。
纳入了 2021 年 2 月至 2022 年 10 月间接受腰椎穿刺(LP)的患者。比较了未接种疫苗和接种疫苗患者的血清 C 反应蛋白(CRP)、中性粒细胞与淋巴细胞比值(NLR)、脑脊液总蛋白含量(CSF-TPc)、脑脊液葡萄糖与血清比值、每立方毫米脑脊液细胞数和脑脊液神经丝轻链(CSF-NfL)。
共纳入 110 例患者,根据接种状况(接种和未接种)和距最后一剂疫苗至 LP 的时间(3 个月内或 3 个月后)首先将其分为三组。各组间 TPc、CSF/S 比值、每立方毫米细胞数、CSF-NfL、CRP 和 NLR 均无差异(均 P>0.05),且与年龄或诊断也无关。当风险时间窗口设置为 6 周时,各组间也未观察到相关差异。
与未接种疫苗的患者相比,神经系统疾病患者在接种针对 SARS-CoV-2 的疫苗后并未出现神经炎症、轴索丢失和全身炎症的迹象。